Ra Pharmaceuticals, Inc.

Adamis Pharmaceuticals Corporation

Masimo Laboratories, Inc.

3m Innovative Properties Company

Children's Hospital Medical Center

Enanta Pharmaceuticals, Inc.

Cercacor Laboratories, Inc.

Zhaolin Wang

Douglas A Treco

Daniel Elbaum

Alonso Ricardo

Zhong Ma

Kristopher Josephson

Hong Zheng

Ping Ye

Nathan Ezekiel Nims

Michelle Denise Hoarty

Kathleen Seyb

Guo-Qing Tang

Ketki Ashok Dhamnaskar

Sarah Jacqueline Perlmutter

Kelley Cronin Larson

Robert P Hammer

Stephen W Stein

Eberhard Schneider

Peter Wagner

Nicolas Cedric Boyer

Gregor Schurmann

Paul Anderson

Peter D Hodson

Michael K Domroese

Alex R Zelenchuk

Emile M Bellott

Christopher R Lambert

Herbert C Chiou

Jerome J Workman

Dongsheng Bu

James J Childs

Hubert A Nienaber

Shirley J Shi

Thomas S Robison

Blake D Walburg

Michelle Denise Arata

Yat Sun Or

Ly Tam Phan

Ying Sun

Tianying Jian

John K Simons

Robert Paul Hammer

The present invention provides polypeptide modulators of complement activity, including cyclic polypeptide modulators. Also provided are methods of utilizing such modulators as therapeutics.

Modulators of complement activity

The present invention provides modulators of complement activity. Also provided are methods of utilizing such modulators as therapeutics.

Modulation of complement activity

Disclosed herein are &#x3b2;-glucosidase (GCase) chaperones and methods of using GCase chaperones in an individual in need thereof. GBA1 mutations lead to GCase deficiency and substrate accumulation, causing Gaucher disease. Currently, no FDA or EMA-approved therapeutic for neuronopathic Gaucher disease is available. Improved GCase activity in brain cells using a chaperone may reduce substrate accumulation and associated pathology. Disclosed herein are novel non-inhibitory chaperone compounds of GCase that have properties of a central nervous system drug. Those compounds effectively restored mutant GCase activity by stabilizing protein and enhancing lysosomal localization and may be useful for chaperone therapy to treat neuronopathic Gaucher disease and likely to Parkinson's disease.

CNS-accessible pharmacological chaperones for treatment of acid &#x3b2;-glucosidase-related disease states

The disclosure describes powder inhalers and dry powder inhaler storage cassettes that include a compartment housing an elongate carrier preloaded with a plurality of doses of finely divided powder comprising a biologically active substance. The compartment is configured such that the preloaded doses are sealed within the compartment and such that the carrier may be advanced from the compartment to the chamber through an exit provided with a moisture barrier sealing system. The moisture barrier sealing system is configured and arranged such that it is relaxable during advancement of the carrier. The sealing system is in sealing configuration prior to an advancement of the carrier, is relaxed upon an advancement of the carrier and is returned to its sealing configuration at the latest after release of the powder associated with the area of the carrier.

Dry powder inhalers

Powder feeding apparatuses () and methods. The powder feeding apparatus () can include first and second cylindrical rollers () adjacent to each other and spaced apart by a gap (). The first roller () can rotate intermittently and independently of the second roller (). The second roller can rotate intermittently and independently of the first roller. Powder from a hopper () is fed through the gap as one or both rollers rotate. The powder feeding method may include a method of feeding powder by intermittently and alternately advancing a first and second roller to dispense powder from the hopper.

Powder feeding apparatus

A dry-powder inhaler comprising a housing comprising at least one air inlet to a first air passage and a second air passage extending from the first air passage and terminating in a mouthpiece; the housing thereby providing a continuous air passage through the at least one air inlet, the first and second air passages, and the mouth piece; a rigid, fixed, powdered-medicament reservoir comprising a base, the reservoir being associated with the first air passage, and together with the first air passage forming a powder chamber; wherein air passing through the powder chamber travels substantially parallel to an upper surface of the reservoir and powdered-medicament positioned on the base in the reservoir, the upper surface of the reservoir having a surface area, and the reservoir having a volume.

Single high dose dry-powder inhaler and method

The present invention provides inhibitors and/or antagonists of plasma kallikrein. Also provided are methods of utilizing the inhibitors as therapeutics.

Peptide and peptidomimetic inhibitors

Growing community of inventors

Wellesley, MA, United States of America

Zhaolin Wang